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Background: We reported previously that 18F-2-fluoro-2-deoxyglucose positron emission tomography/ computed
tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors
(TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG
PET/CT to long-term prognosis with an expanded number of patients and period of observation.
Methods: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was
performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment
to progression free survival (PFS) and overall survival (OS) were investigated.
Results: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing
high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271)
and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases)
were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased< 20% was shorter than that
of the patients whose SUVmax decreased≥ 20% (P= 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of
patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter
sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448).
The patients were classified into three response groups: good responder (diameter sum did not increase, and
SUVmax decreased≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased< 20%),
and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good,
intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate
P= 0.0366, intermediate vs. poor P= 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days,
469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P= 0.0385, intermediate vs. poor P= 0.0305,
log-rank test).
Conclusions: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after
1 month can predict PFS and OS.* Correspondence: nakaigan@med.yokohama-cu.ac.jp
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Renal cell carcinoma (RCC) accounts for 3% of all adult
cancers [1]. Approximately 30% of patients are diagnosed
with metastases and an additional 20-40% of patients
develop metastases after radical nephrectomy with cura-
tive intent [2,3]. Cytokine therapies were the only sys-
tematic treatments available for advanced RCC for a
long time, and the outcome of patients with metastatic
RCC has been poor, with a median survival time of 10 to
21 months [4,5].
Recently, the oncogenic mechanism of RCC has been
elucidated and drugs that target relevant biological path-
ways have been developed. Tyrosine kinase inhibitors
(TKIs) such as sunitinib and sorafenib which target vascu-
lar endothelial growth factor (VEGF) receptors improved
the prognosis of patients with metastatic RCC [6,7]. The
antitumor activity of TKIs is not cytotoxic, like classical
antitumor therapeutics, but rather cytostatic, suppressing
biological activity by inhibiting angiogenesis. Practically,
some RCCs treated with the TKIs do not decrease in
tumor volume but enter a period of long-term dormancy,
without enlargement of volume or novel metastasis. It has
been suggested that a new assessment focusing not only
on the volume of the tumors, but also biological activities
to evaluate the antitumor activity of TKIs is necessary.
18F-2-fluoro-2-deoxyglucose positron emission tomog-
raphy/ computed tomography (FDG PET/CT) is a useful
non-invasive tool to evaluate glucose metabolic status,
which can be the index of biological activity of cancer.
Although PET has not been generally used for the
screening of RCC due to the urinary excretion of the
radiotracer, which can mask the presence of primary
lesions [8,9], several investigators have reported recently
that FDG-PET/CT had sufficient potential to evaluate
advanced RCCs [10-12]. We previously reported the
potential of FDG PET/CT as a tool to evaluate the early
response to TKIs in advanced RCC, but the number of
cases was small and the observation period was short [13].
This time, we investigated the potential with an expanded
number of patients and period of follow-up.
Methods
Patients
Thirty-five patients were enrolled in this study. Patients
had to be referred to Yokohama City University before
the start of their treatment, from June 2008 until March
2011. This was a prospective study to clinically follow
enrolled patients planning to undergo TKI therapy for
advanced RCC. The pathologies of enrolled cases were
confirmed by prior nephrectomy or biopsy. Patients
with uncontrolled diabetes mellitus (blood glucose level
>150 mg/dL) , with other known malignancies, and those
treated with therapeutics during the 2 weeks prior to the
scan were excluded. The study protocol was approved bythe Yokohama City University Institutional Review Board.
Written informed consent was obtained from all patients.
The decision for patients to undergo therapy was made
before the evaluation by PET/CT.
Treatment
Sunitinib was given orally once a day at the dose of 50 mg
in 6-week cycles consisting of 4 weeks of treatment fol-
lowed by 2 weeks without treatment. Oral sorafenib
800 mg was given daily. The dose of sunitinib was
reduced to 37.5 or 25 mg and that of sorafenib was
reduced to 600 or 400 mg according to pretreatment
general condition or major adverse events during treat-
ment. Treatment was continued until disease progression,
unacceptable adverse events, request by the patient, or
surgery including nephrectomy.
Imaging
Patients fasted for at least 6 hours prior to intravenous
injection of 18F FDG. PET/CT images were obtained
using a PET/CT system (Aquiduo 16; Toshiba Medical
Systems, Tokyo, Japan). PET/CT images were acquired
from the top of the head to the mid thigh at 60 min after
intravenous injection of 2.5 MBq/kg of [18F] FDG. A
low-dose non-contrasted CT scan was acquired first and
used for attenuation correction. Emission images were
acquired in 3-dimensional mode for 2 min per bed pos-
ition. After PET acquisition, contrast-enhanced CT was
performed with a 2-mm slice thickness, 120 kV, 400 mA,
0.5 s/tube rotation, from the top of the head to the
mid thigh, with breath holding. A total of 100 ml con-
trast medium (iopamidol) was administered intraven-
ously at a rate of 1.0 ml/s. The scan delay was set at
120 s after starting the injection of contrast material.
The patients with serum creatinine level >1.5 mg/dL
were examined without contrast material. Images were
reconstructed by attenuation-weighted ordered-subset
expectation maximization (OSEM) (four iterations,
fourteen subsets, 128 ´ 128 matrix, with 5-mm Gaussian
smoothing). The standardized uptake value (SUV) was
determined according to the standard formula, with activ-
ity in the volume of interest (VOI) recorded as Bq per ml /
injected dose in Bq per weight (kg). The maximum SUV
(SUVmax) was recorded using the maximum pixel activity
within the VOI. To obtain the SUVmax of the individual
patient, the SUV of all lesions in tumors diagnosed as
RCC by CT imaging were analyzed.
Statistical analysis
Cox proportional hazards model was used to assess the
impacts of pretreatment SUVmax, SUVmax change ratio,
total diameter change ratio, and clinical parameters on pro-
gression-free survival. The progression-free survival and
overall survival curves were estimated by the Kaplan-Meier
Table 1 Characteristic of 30 patients
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the log-rank test.
The statistical difference of SUVmax and SUVmax
change between clear cell carcinoma and papillary carcin-
oma was determined by two-side Mann-Whiteney’s U-test.
All statistical analyses were carried out with SPSS software
(SPSS, Inc, Chicago, IL). Significance was assigned at
P< 0.05.
Results
Patients characteristics and intervention
Thirty-five patients were enrolled in this prospective
study and evaluated by FDG PET/CT before treatment
with TKIs (sunitinib 19 cases, sorafenib 16 cases). When
the highest lesion SUV in individual patients was defined
as SUVmax, SUVmax of the 35 patients ranged between
2.3 and 16.6 (mean 9.0). The patients with RCC tumors
showing high SUVmax demonstrated short progression-
free survival (PFS) (P= 0.024, hazard ratio 1.137, 95% CI
1.017-1.271) and short overall survival (OS) (P =0.004,
hazard ratio 1.210 95% CI 1.062-1.379).
Thirty patients (sunitinib 16 cases, sorafenib 14 cases)
were evaluated again after 1 month of treatment; the
other, 5 patients (4 clear cell and 1 sarcomatoid) demon-
strated deterioration of general status due to rapid pro-
gression within 1 month. The SUVmax range of the 5
patients was 8.9-16.6 (mean 14.1). The clinical character-
istics of the 30 patients are detailed in Table 1. There
were 25 men and 5 women. The mean age was 64 years
(range, 32–80). Of all 30 patients, 23 had pure clear cell
carcinoma, 5 had papillary carcinoma, 1 had clear cell
carcinoma mixed with sarcomatoid component, and 1
long-term dialysis patient had a heterogeneous pathology
with clear cell type and papillary type. The mean SUV-
max was 8.1 (range, 2.3-16.1). The mean SUVmax of 23
pure clear cell carcinoma was 7.6(range, 2.3-14.8) and the
mean SUVmax of 5 papillary carcinoma was 9.7 (range,
3.9-16.1). There was not statistical difference (P =0.413).
The SUVmax of clear cell/sarcomatoid was 9.1. The SUV-
max of the celar cell/papillary was 9.5. According to
Memorial Sloan-Kettering Cancer Center (MSKCC)
classification [14], one patient had favorable risk, 21
intermediate risk, and 8 poor risk. Twenty-two patients
had undergone nephrectomy. Nineteen patients had no
previous systematic therapies. Three patients had been
treated previously with sorafenib and the treatment
ended more than 1 month before the pretreatment
evaluation by FDG PET/CT. Nine patients had previously
been treated by IFN-alpha, and 2 by chemotherapy.
Clinical outcome of 30 patients
The mean duration of observation was 458 days (range,
67–1114). At the date of analysis, 18 patients showed
progressive disease (PD) as evaluated by RECIST version1.1 and 10 patients had died due to progression of RCC.
No patients had died for other reasons. The median PFS
was 209 days (range, 27–887). Three patients (sunitinib,
2; sorafenib, 1) underwent nephrectomies after TKI treat-
ment. Of the 14 patients treated with sorafenib, 10 patients
changed to sunitinib due to PD, and 4 of the 10 patients
changed to everolimus sequentially. One of the 14
sorafenib-treated patients changed directly to everolimus.
Of the 16 patients treated with sunitinib, 4 patients chan-
ged to everolimus and 1 patient changed to sorafenib due
to PD.
The impacts of some clinical parameters on PFS were
analyzed by Cox proportional hazards modeling (Table 2).
There was statistical difference only between the patients
with liver metastasis and the patients without liver metas-
tasis (P =0.004).The assessment by FDG PET/CT
In pretreatment FDG PET/CT of the 30 patients who
underwent two-time assessment, FDG accumulation was
detected in 95 lesions of 107 lesions (89%) whose dia-
meters were 1.0 cm or more. The mean number of RCC
lesions in the individual patients was 3.5 (range, 1–9).
Table 2 Univariate Cox progression-free survival analyses
of various clinical parameters
Univariate analysis
Clinical Parameters P-value HR 95%CI
sunitinib vs. sorafenib 0.341 1.585 0.614-4.096
clear cell vs. papillary 0.087 2.841 0.860-9.379
nephrectomy: yes vs. no 0.620 0.725 0.203-2.590
pretreatment: yes vs. no 0.205 0.500 0.171-1.459
previous TKI: yes vs. no 0.380 0.510 0.113-2.293
previous IFN: yes vs. no 0.056 0.284 0.078-1.033
number of lesions: 1–2 vs. 3 ≥ 0.056 3.046 0.971-9.559
lung metastasis: only vs. others 0.359 0.552 0.155-1.967
bone metastasis: no vs. yes 0.927 0.942 0.264-3.365
liver metastasis: no vs. yes 0.004 7.672 1.891-31.130
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treatment started was day 31 (range, 27–47). The median
SUVmax in the second FDG PET/CT was 7.1 (range,
3.7-15.5). The mean ratio of SUVmax change compared
with pretreatment FDG PET/CT was −18% (range, -55 to
65%). The mean ratio of the diameter change was −6%
(range, -30 to 30%). No lesion remitted completely. A
new lesion appeared in only 1 patient. The mean ratio of
SUVmax change in clear cell carcinoma was −14.0%
(range, -54.9%- 65.2%), and that in papillary carcinoma
was −1.1%(range, -35.4%- 15.7%). The mean ratio of the
diameter in in clear cell carcinoma was −5.7%(range,
-30.2%- 29.7%), and that in papillary carcinoma was
−6.5%(range, -22.4%- 13.8%). The ratios of SUVmax














Figure 1 The association between PFS and change ratios of SUVmax
The information about PFS (days) was added as height to the 2-dimension
and those of tumor diameters sum (vertical axis) after 1 month in individua
does not increase and SUVmax decreases≥ 20%), yellow bars indicate thos
SUVmax decreases< 20%), and red bars indicate those of poor respondersbetween clear cell carcinoma and papillary carcinoma
(SUVmax change: p = 0.193, diameter change: p = 0.954).
According to the European Organization for Research
and Treatment of Cancer (EORTC) criteria [15], in which
the SUV cut-off point is 25%, 9 patients had a partial meta-
bolic response, 14 patients had SD, and 7 had PD. None
achieved complete remission (CR). There was no statistical
association between the evaluation by EORTC criteria
and PFS. However, the PFS of the patients whose tumor
SUVmax decreased< 20% after 1 month was shorter than
that of those whose tumor SUVmax decreased≥ 20%
(P=0.027, Cox hazard ratio 3.043, 95% CI 1.134-8.167).
Additionally, the PFS of patients whose tumor diameter
sum increased after 1 month was shorter than that of the
patients whose tumors diameter sum did not increase
(P=0.006, hazard ratio 4.555, 95% CI 1.543-13.448).
Using these two predictive factors, we defined new and
simple criteria for evaluating tumor response to TKI of
advanced RCC as follows: good responder, diameter sum
does not increase and SUVmax decreases≥ 20%; inter-
mediate responder, diameter sum does not increase and
SUVmax decreases< 20%; and poor responder, diameter
sum increases or one or more new lesions appear.
According to the new criteria, the 30 patients were
classified into 12 good responders (blue bars in Figure 1),
10 intermediate responders (yellow bars in Figure 1), and
8 poor responders (red bars in Figure 1). The median PFS
of good, intermediate, and poor responders were 458 ±
146 days, 131± 9 days, and 88± 26 days, respectively.
There was a statistical difference among these three groups
(good vs. intermediate P=0.0366, intermediate vs. poor
P = 0.0097, log-rank test) as shown in Figure 2. Add-
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Figure 2 Kaplan-Meier curves of progression-free survival in 30 patients according to our response criteria.
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125 days, respectively (good vs. intermediate P=0.0385,
intermediate vs. poor P=0.0305, log-rank test) as shown in
Figure 3.
Discussion
This work demonstrated that the early assessment of
response to TKIs using a combination of FDG uptake
and tumor size could predict not only the PFS but also
the OS of patients with advanced RCC. To our know-
ledge, it is the first to address this issue. The benefit of
assessment by FDG uptake as well as is the ability to
evaluate the biological dormancy induced by the treat-
ments. Although the prognosis of advanced RCC was
dramatically improved with the development of TKIs such
as sunitinib or sorafenib, the best responses were usually
found in stable diseases according to RECIST. Indeed,
treatment by sunitinib is associated with 31% overall re-
sponse rate and that by sorafenib was only 2% in clinical
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Figure 3 Kaplan-Meier curves of overall survival in 30 patients accordin tumor volume but maintain long-term dormancy with-
out enlargement of volume or novel metastasis. But there
have been no clinical answers to the question of whether
an individual case treated with TKIs whose tumors did not
decrease in size should continue the treatment or change
to other therapeutic options including other TKIs and
mammalian target of rapamycin (mTOR) inhibitors, which
have been reported to benefit patients with advanced RCC
[16,17]. This was primarily because there has been no bio-
logical marker to evaluate the biological activity of RCCs,
especially the dormancy induced by TKIs. In this regard,
FDG PET/CT is a useful tool to evaluate glucose meta-
bolic status, which can be the index of biological activity
of cancer; a decrease of FDG accumulation can express
the biological dormancy of RCC induced by TKI treat-
ment. Indeed, a patient with only 7% decrease in tumor
diameter sum and 20% decrease in SUVmax maintained
an SD status for 887 days (Figure 4) and another with only
3% decrease in the tumor diameter sum and 20% decrease
in SUVmax achieved 458 days of SD in our series.days200
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Figure 4 A patient demonstrating long tumor dormancy. 57 y.o. female with mediastinal lymph node metastasis. CT images at (A) pretreatment
state and (B) post-treatment state, PET images at (C) pretreatment state and (D) post-treatment state, fused PET/CT images at (E) pretreatment state
and (F) post-treatment state. The diameter of mediastinal lymph node decreased 7% and its SUVmax decreased 20% in post-sunitinib treatment state.
She maintained an SD for 887 days.
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other than by tumor volume. Krajewski KM et al. previously
reported that tumor attenuation in contrast-enhanced CT
(CECT) predicts the outcome of RCC patients treated with




Figure 5 A patient demonstrating rapid progression. 59 y.o. male with
and (B) post-treatment state, PET images at (C) pretreatment state and (D)
and (F) post-treatment state. The CT images showed that the metastatic le
and the enhancement was attenuated apparently in post-sorafenib treatmdemonstrated attenuation had a decrease in SUVmax and
their prognoses proved to be good. However, we experi-
enced one case in which tumors showed apparent attenu-
ation of contrast-enhancement but a decrease of only 5% in






thoracic vertebral metastasis. CT images at (A) pretreatment state
post-treatment state, fused PET/CT images at (E) pretreatment state
sion had homogeneous contrast enhancement at pretreatment status
ent. The SUVmax decreased only 5%. He died on day 88.
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the inhibition of angiogenesis, and that attenuation was not
a sufficient condition to reflect tumor dormancy. Addition-
ally, the renal function of most patients with advanced
RCC is deteriorated due to nephrectomy or the existence
of the original tumor, and CETC entails a risk of worsen-
ing kidney function. So, we think that the evaluation by
FDG PET/CT is more precise and safer than that by
CECT.
However, it was not sufficient to assess the response to
TKIs of RCCs by FDG uptake alone because there were
some RCC cases with decreased SUVmax but increased
tumor volume, and their prognoses were poor as shown
Figure 1. In our series, 3 patients demonstrated a de-
crease in SUVmax ≥ 20% but an increase in tumor size
after 1 month, and their PFSs were very short: 28, 28,
and 146 days, respectively. Additionally, the classification
of our series by EORTC criteria, which assess the re-
sponse by FDG uptake, was not statistically associated
with prognosis. Kayani et al. previously reported that the
assessment of patients with RCC treated with sunitinib
by FDG uptake alone after 4 weeks failed to predict the
disease course [20]. These results suggested the existence
of RCCs that progress independently of glucose uptake,
and emphasize the need for a combination assessment of
both tumor size and FDG uptake.
Some questions remain. We defined metabolic response
as a ≥20% reduction of SUVmax in the novel criteria we
advocated. The EORTC proposed a SUV diminution of
15-25% for a partial response after the first cycle. Kayani
et al. the defined cut-off point as 20% when they evalu-
ated the response to sunitinib in metastatic RCC and
succeeded in predicting the disease course by assessment
after 16 weeks. Lyrdal et al. reported that responders with
a decrease of ≥20% FDG accumulation to sorafenib had
a long OS. A further study expanding the number of
patients is necessary to verify this cut-off point.
Conclusion
The evaluation of RCC response to TKI treatment by
tumor size and FDG uptake using FDG PET/CT after
1 month can predict not only the duration of response
to TKIs, but also survival duration. Early assessment by
FDG-PET/CT provides useful information to determine
strategies for individual patients with advanced RCC.
However, larger studies are needed to confirm these pre-
liminary results.
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